Literature DB >> 15763336

Serum antibodies against the hepatitis C virus E2 protein mediate antibody-dependent cellular cytotoxicity (ADCC).

Jacob Nattermann1, Angelika Maria Schneiders, Ludger Leifeld, Bettina Langhans, Monika Schulz, Geneviève Inchauspé, Bertfried Matz, Hans H Brackmann, Michael Houghton, Tilman Sauerbruch, Ulrich Spengler.   

Abstract

BACKGROUND/AIMS: The role of antibody dependent cellular cytotoxicity (ADCC) in HCV infection is unclear at present. Antibodies mediating ADCC are usually directed against viral envelope proteins. As cell surface expression of the HCV envelope E2 protein has been shown, the HCV E2 protein is an especially promising candidate target for ADCC.
METHODS: Sera from patients with acute (n=6), self-limited (n=11) and chronic (n=19) HCV infection were analyzed in this study. Sera reacting with cell-bound HCV antigens were examined in a flowcytometric cytotoxicity assay using antigen-coated JOK-1 cells as targets.
RESULTS: We found that sera from all stages of HCV infection reacted with cells loaded with HCV E2. E2-specific ADCC was observed in patients with acute (n=3/6), self-limited (n=5/11) and chronic (n=13/19) hepatitis C and was closely related to fluorescence intensity in the E2-binding assay (r=0.67, P<0.001).
CONCLUSIONS: We conclude that E2-antibodies from all stages of HCV infection can mediate ADCC. Thus, the role of this process in the pathogenesis of chronic hepatitis C should be further elucidated.

Entities:  

Mesh:

Substances:

Year:  2005        PMID: 15763336     DOI: 10.1016/j.jhep.2004.12.018

Source DB:  PubMed          Journal:  J Hepatol        ISSN: 0168-8278            Impact factor:   25.083


  14 in total

1.  Non-neutralizing epitopes induce robust hepatitis C virus (HCV)-specific antibody-dependent CD56+ natural killer cell responses in chronic HCV-infected patients.

Authors:  L Long; M Jia; X Fan; H Liang; J Wang; L Zhu; Z Xie; T Shen
Journal:  Clin Exp Immunol       Date:  2017-04-07       Impact factor: 4.330

2.  Preclinical evaluation of two neutralizing human monoclonal antibodies against hepatitis C virus (HCV): a potential treatment to prevent HCV reinfection in liver transplant patients.

Authors:  Rachel Eren; Dorit Landstein; Dov Terkieltaub; Ofer Nussbaum; Arie Zauberman; Judith Ben-Porath; Judith Gopher; Rachel Buchnick; Riva Kovjazin; Ziva Rosenthal-Galili; Sigal Aviel; Ehud Ilan; Yariv Shoshany; Lewis Neville; Tal Waisman; Ofer Ben-Moshe; Alberto Kischitsky; Steven K H Foung; Zhen-Yong Keck; Orit Pappo; Ahmed Eid; Oded Jurim; Gidi Zamir; Eithan Galun; Shlomo Dagan
Journal:  J Virol       Date:  2006-03       Impact factor: 5.103

3.  Interactive effects of immunoglobulin gamma and human leucocyte antigen genotypes on clearance and persistence of infection with hepatitis C virus.

Authors:  J P Pandey; M A Montes-Cano; J Aguilar-Reina; M F Gonzalez-Escribano
Journal:  Clin Exp Immunol       Date:  2007-10-09       Impact factor: 4.330

4.  Hepatitis C virus (HCV)-induced immunoglobulin hypermutation reduces the affinity and neutralizing activities of antibodies against HCV envelope protein.

Authors:  Keigo Machida; Yasuteru Kondo; Jeffrey Y Huang; Yung-Chia Chen; Kevin T-H Cheng; Zhenyong Keck; Steven Foung; Jean Dubuisson; Vicky M-H Sung; Michael M C Lai
Journal:  J Virol       Date:  2008-04-16       Impact factor: 5.103

Review 5.  Virus-related liver cirrhosis: molecular basis and therapeutic options.

Authors:  Ji Lin; Jian-Feng Wu; Qi Zhang; Hong-Wei Zhang; Guang-Wen Cao
Journal:  World J Gastroenterol       Date:  2014-06-07       Impact factor: 5.742

6.  Immunoglobulin allotypes influence IgG antibody responses to hepatitis C virus envelope proteins E1 and E2.

Authors:  Janardan P Pandey; Yuqun Luo; Robert C Elston; Yuping Wu; Frances Hite Philp; Jacquie Astemborski; David L Thomas; Dale M Netski
Journal:  Hum Immunol       Date:  2008-03-10       Impact factor: 2.850

7.  Quantitative analysis of immunoglobulin subclasses and subclass specific glycosylation by LC-MS-MRM in liver disease.

Authors:  Wei Yuan; Miloslav Sanda; Jing Wu; John Koomen; Radoslav Goldman
Journal:  J Proteomics       Date:  2015-01-09       Impact factor: 4.044

Review 8.  To Include or Occlude: Rational Engineering of HCV Vaccines for Humoral Immunity.

Authors:  Felicia Schlotthauer; Joey McGregor; Heidi E Drummer
Journal:  Viruses       Date:  2021-04-30       Impact factor: 5.048

9.  Hepatitis C VLPs delivered to dendritic cells by a TLR2 targeting lipopeptide results in enhanced antibody and cell-mediated responses.

Authors:  Brendon Y Chua; Douglas Johnson; Amabel Tan; Linda Earnest-Silveira; Toshiki Sekiya; Ruth Chin; Joseph Torresi; David C Jackson
Journal:  PLoS One       Date:  2012-10-16       Impact factor: 3.240

Review 10.  Clinical development of monoclonal antibody-based drugs in HIV and HCV diseases.

Authors:  Michela Flego; Alessandro Ascione; Maurizio Cianfriglia; Stefano Vella
Journal:  BMC Med       Date:  2013-01-04       Impact factor: 8.775

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.